What is the role of desmopressin (DDAVP) in the treatment of von Willebrand disease (vWD) type 3?

Updated: Dec 30, 2019
  • Author: Eleanor S Pollak, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

Individuals with vWD type 3 have a virtually complete deficiency of vWF. Thus, DDAVP, which causes the release of stored vWF, has no effect in patients with this disorder.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!